Sun Pharma Corporate Overview

Our Specialty Portfolio Odomzo Indication For LABCC (locally advanced basal cell carcinoma) SUN PHARMA • Currently marketed in US, Germany, France, Denmark, Switzerland, Australia and Israel Yonsa Bromsite Xelpros Sprinkle Portfolio • Indication - For metastatic castration resistant prostate cancer in combination with methylprednisolone • Launched in US in May 2018 - Indication For prevention of ocular pain & treatment of inflammation following cataract surgery • Launched in US in November 2016 • Indication - For reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension BAK (Benzalkonium chloride) free form of latanoprost Launched In US in January 2019 • Products using sprinkle technology for patients who have difficulty swallowing Sprinkle versions of metoprolol (cardiology), rosuvastatin (cardiology) & duloxetine (neuro-psychiatry) commercialized in US between 2018-2019 Therapeutic solutions for long-term care (LTC) patients © Sun Pharmaceutical Industries Limited. All Rights Reserved. 9

View entire presentation